Drug Shortage Report for GENTAMICIN(E)
Report ID | 179918 |
Drug Identification Number | 02082152 |
Brand name | GENTAMICIN(E) |
Common or Proper name | GENTAMICIN(E) |
Company Name | BAXTER CORPORATION |
Market Status | MARKETED |
Active Ingredient(s) | GENTAMICIN |
Strength(s) | 1.6MG |
Dosage form(s) | SOLUTION |
Route of administration | INTRAVENOUS INTRAVENOUS |
Packaging size | 50mL (JB0852P) |
ATC code | J01GB |
ATC description | AMINOGLYCOSIDE ANTIBACTERIALS |
Reason for shortage | Demand increase for the drug. |
Anticipated start date | 2023-01-09 |
Actual start date | 2023-01-09 |
Estimated end date | 2023-02-06 |
Actual end date | 2023-02-06 |
Shortage status | Resolved |
Updated date | 2023-02-07 |
Company comments | Baxter product Gentamicin Sulfate Injection in 0.9% Sodium Chloride Injection 1 mg / mL (100 mg / 100 mL) (JB0863) is available as a substitute if aligned with clinical practice. |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 7125 MISSISSAUGA ROAD MISSISSAUGA, ONTARIO CANADA L5N 0C2 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v8 | 2023-02-07 | English | Compare |
v7 | 2023-02-06 | French | Compare |
v6 | 2023-02-06 | English | Compare |
v5 | 2023-01-30 | French | Compare |
v4 | 2023-01-30 | English | Compare |
v3 | 2023-01-10 | English | Compare |
v2 | 2023-01-05 | French | Compare |
v1 | 2023-01-05 | English | Compare |
Showing 1 to 8 of 8